Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2007-08-15 Regulatory Filings
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
BIT225 Phase I Clinical Trial Successfully Completed 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Biotron Limited about the successful completion of a Phase I clinical trial for their drug BIT225. It includes clinical trial design, results, and future plans for further trials. The content focuses on clinical trial progress and drug development milestones rather than financial results, regulatory certifications, or shareholder information. It is not an annual or interim financial report, audit report, earnings release, or any form of regulatory filing. It is a corporate announcement related to clinical trial progress, which typically falls under general regulatory announcements or company updates. Given the nature and length of the document (over 6,000 characters) and the absence of financial data or shareholder meeting content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other specific categories.
2007-08-15 English
BIT225 Highly Synergistic with Current Anti-HCV Therapies 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement from Biotron Limited dated 7 August 2007, addressed to the Australian Stock Exchange. It announces a significant advancement in the development of their antiviral drug BIT225, including research results and plans for clinical studies. The document is only 2 pages and contains no financial statements, detailed financial data, or regulatory filings. It is not a full annual or interim report, nor an earnings release. It is a corporate announcement about drug development progress and patent filing, typical of a regulatory announcement to the stock exchange. The document does not fit into categories like M&A, capital update, or management changes. Given its length and content, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2007-08-06 English
Response to ASX Query 4 pages ?Kb
Regulatory Filings
2007-08-06 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. The document covers a quarterly period ending 30 June 2007. The presence of substantive financial data and analysis for a quarter, including cash flow statements and notes, indicates this is a comprehensive quarterly financial report. The document length is over 7,000 characters, which supports it being a full report rather than a brief announcement. The document matches the characteristics of an Interim / Quarterly Report (IR) as it provides detailed financial statements and analysis for a period shorter than a full fiscal year. Q4 2007
2007-07-29 English
HIV Drug Data Presented to International Conference 1
Regulatory Filings Classification · 95% confidence The document is a short announcement (only 2592 characters) from the company Biotron Limited, dated 25 July 2007, addressed to the Australian Stock Exchange. It announces that the company is presenting preclinical efficacy data for its HIV drug at an international conference (IAS 2007). The content focuses on the presentation of scientific data and progress in clinical trials, but it does not contain any financial statements, detailed financial analysis, or regulatory filings. It is not a full report, nor does it announce voting results, management changes, or capital activities. The document is essentially a news release or update about a scientific presentation. Given its length and content, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2007-07-24 English
Hepatitis B Antiviral Program and Phase I Trial Update 1
Regulatory Filings Classification · 95% confidence The document is a short announcement from Biotron Limited dated 10 July 2007, addressed to the Australian Stock Exchange. It provides an update on the expansion of the company's antiviral program to Hepatitis B virus and a Phase I clinical trial update. The content is a brief corporate announcement about research progress and clinical trial status, without any detailed financial data, comprehensive report, or regulatory filing. The document length is only 2141 characters, which is quite short and typical for a press release or corporate update rather than a full report. There is no indication that this is a full Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory filing. It is also not a certification or voting result. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2007-07-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.